This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen, Inc. Reports On Additions To Its Industry-Leading ADC Technology Portfolio At AACR-NCI-EORTC Conference

ImmunoGen, Inc. (Nasdaq: IMGN) today reported on additions to the Company’s portfolio of antibody-drug conjugate (ADC) technologies at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting being held in Boston, MA. 1,2,3 Of particular interest were presentations on the Company’s new platform of DNA-acting payload agents ImmunoGen has created to further extend the opportunity for ADC cancer treatments.

New Platform of DNA-Acting Payload Agents

ImmunoGen scientists presented preclinical data on the Company’s IGN platform of DNA-acting agents, developed for use in ADCs. 1,2 These agents complement the Company’s existing, successful platform of tubulin-acting payload agents (e.g., DM1, DM4). ImmunoGen created its IGNs to expand the opportunity for ADC therapies – to enable the development of effective ADCs for cancers such as those not sensitive to tubulin-acting agents, those with low levels of antigen expression, and those with multidrug resistance.

As reported today, ImmunoGen scientists created IGN di-imines that demonstrate potent anticancer activity in preclinical testing – both alone and as the payload component of an ADC. They then identified that certain IGN modifications greatly enhance the tolerability of IGN-ADCs, without loss of potency, enabling achievement of anticancer agents demonstrating a notable therapeutic window in preclinical models.

The presentations today include data showing in vivo activity and tolerability, on both an acute and sustained basis, of ADCs utilizing such modified IGNs (IGN mono-imines). Data were reported for IGN-ADCs to different antigen targets and included activity against both hematological and solid tumors.

Also reported were data showing the marked impact of linker selection on achievement of an optimized ADC with these IGN payload agents. 2 ImmunoGen scientists have previously reported on the impact of linker selection on achievement of an optimized ADC with the Company’s tubulin-acting payload platform. 4

“Our technologies and approaches are designed to achieve effective, well-tolerated and producible ADC products,” commented John Lambert, PhD, ImmunoGen EVP and Chief Scientific Officer. “While there can be a tendency in this field to want to focus on one element of an ADC – the linker, payload or manufacturing approach – experience shows that ADCs are best thought of as integrated systems.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.01 0.00%
FB $99.75 0.00%
GOOG $682.74 0.00%
TSLA $147.99 0.00%
YHOO $27.05 0.00%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs